Remarkably, RETA-induced protection extends to a lung cancer model with 50% reduced tumor engraftment, significantly delayed tumor onset, and mitigated tumor progression, with a 17-fold reduction in tumor volume compared to controls
The subjects also reported/demonstrated: fewer muscle pains improved sleep a lessening of fatigue and depression improvement in oxygen flow around the body Decrease Anxiety and Enhance Mood Aberrations in brain substances known as neurotransmitters are commonly associated with mood disorders and epilepsy
Its a newer generation triple-agonist medication targeting GLP-1, GIP, and glucagon receptors
Many people experience cognitive changes including difficulty concentrating, memory problems, or mental fogginess
The precise timeline based on clinical trial tracking: Weeks 1-3: Mild symptoms beginning, most patients adapting to medication Weeks 4-8: Peak side effect period highest nausea, GI symptoms at their worst Weeks 9-12: Rapid improvement, most GI symptoms resolving Weeks 13-24: Minimal symptoms for most, discontinuation rate drops to under 2% Weeks 25-48: Essentially no side effects for 85%+, focus shifts to weight maintenance According to research published in the New England Journal of Medicine on GLP-1 agonists, this pattern is consistent across the entire class of incretin-based therapies
